Biocon Limited is an Indian biopharmaceutical company based in Bangalore, Karnataka. The company manufactures generic active pharmaceutical ingredients (APIs) and finished dosage forms, and sells them in over 75 countries. Biocon’s products include insulin, statins, immunosuppressants, and anti-cancer drugs. The company also has a joint venture with Mylan, called Mylan-Biocon Biologics, which manufactures biosimilars.
Biocon was founded in 1978 by Kiran Mazumdar-Shaw. The company initially focused on producing enzymes for the brewing and distilling industries. It later diversified into other areas such as biotechnology, pharmaceuticals, and healthcare. Biocon is the first Indian company to receive approval from the US Food and Drug Administration (FDA) for a biosimilar product.
The company’s mission is to “provide affordable and innovative medicines for chronic diseases”. Biocon’s vision is to be a “global enterprise delivering affordable innovation to patients”.
Biocon has a strong research and development (R&D) focus. The company has over 1,200 scientists working in R&D, and has filed over 1,000 patents. Biocon’s R&D expenditure was ?1,847 crore (US$270 million) in FY 2019.
Biocon has a number of manufacturing facilities in India and Malaysia. The company’s products are sold in over 75 countries. Biocon has a joint venture with Mylan, called Mylan-Biocon Biologics, which manufactures biosimilars.
Biocon is a publicly listed company. Its shares are traded on the Bombay Stock Exchange and the National Stock Exchange of India. As of March 2020, the company had a market capitalization of ?62,837 crore (US$8.9 billion).
Biocon is a member of the Nifty 50, an index of the 50 largest and most liquid stocks on the National Stock Exchange of India. The company is also a constituent of the S&P BSE SENSEX, an index of the 30 largest and most liquid stocks on the BSE.